Idarubicin

Idarubicin ball and stick

Idarubicin is an anthracycline antileukemic medication renowned for its significant role in managing various forms of leukemia. As a derivative of daunorubicin, this molecule exhibits increased lipophilicity, which expedites its cellular uptake. Notably, its mechanism hinges on DNA interaction and consequential obstruction of the enzyme topoisomerase II.

Chemical Characteristics[edit]

Idarubicin, or 4-demethoxydaunorubicin, is distinguishable from daunorubicin due to its absent methoxy group. This structural deviation accentuates its lipophilic traits, boosting cellular absorption^[1].

Mechanism of Action[edit]

Its antileukemic activities are ascribed to several interconnected mechanisms:

DNA Interaction: Idarubicin integrates with DNA, obstructing the DNA's inherent flexibility.
Topoisomerase II Inhibition: It impedes the enzyme topoisomerase II, blocking the unwinding of DNA strands^[2].
Histone Eviction: Like other anthracyclines, idarubicin induces histone removal from chromatin, potentially modulating gene expression.

Therapeutic Use[edit]

Categorized within antitumor antibiotics, its clinical implications comprise:

Synergy with cytosine arabinoside for first-line treatment against acute myeloid leukemia (AML)^[3].
Addressing acute lymphoblastic leukemia (ALL).
Intervention in Chronic myelogenous leukemia (CML) during its blast crisis phase.

Trade names differ based on regional availabilities:

Zavedos in the UK
Idamycin in the USA^[4].

Adverse Effects[edit]

Treatment recipients might encounter several side effects, common ones being:

Diarrhea
Stomach cramps
Nausea
Vomiting

Healthcare practitioners should closely monitor these signs to ensure patients' comfort and therapy compliance.

Conclusion[edit]

Idarubicin remains a linchpin in leukemia treatment. Its distinct mode of action and established efficacy afford patients grappling with these blood malignancies a beacon of hope. Yet, the pivotal task remains to juxtapose its therapeutic advantages with potential adverse events, ensuring paramount patient care.

References[edit]

↑ Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229.
↑ Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 May;45(5):649-56.
↑ Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9.
↑ Thomas X, Archimbaud E. Idarubicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 1997 Oct;23(5-6):257-66.

This WikiMD article can only be edited by registered and verified editors. You can log in or register.

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229.

[2] Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 May;45(5):649-56.

[3] Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9.

[4] Thomas X, Archimbaud E. Idarubicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 1997 Oct;23(5-6):257-66.

[1]

[2]

[3]

[4]